IASLC

A randomized phase 2 study found that 30 Grays (Gy) in 1 fraction is equivalent to 60 Gy in 3 fractions in terms of toxicity and survival.

Allowing patients with non-squamous non-small cell lung cancer (NSCLC) to cross over demonstrated a progression-free survival (PFS) benefit.

Double mutations do not significantly decrease overall survival (OS), but do alter progression-free survival (PFS) under first line treatment.

Brigatinib has shown substantial clinical activity among patients with ALK-positive non-small cell lung cancer (NSCLC) who have brain metastases.

Institutional-level differences in the quality of care of patients with NSCLC are associated with differences in stage-stratified and overall survival (OS).

Researchers described “modest success” in a systematic multi-step clinical program to improve tobacco practices.

Next-generation sequencing (NGS) of circulating DNA (ctDNA) could be used to identify emergent resistance mutations.

Tumor genomes in tobacco users with non-small cell lung cancer (NSCLC) have genetic alterations that are associated with poor outcomes.